Me-Can has been updated with an additional 7-11 years of follow-up in Sweden, Norway, and Austria, and additional participants and variables have been added. Me-Can 2.0 studies will include up to 814,000 individuals and 83,000 incident cancers. The first studies will be finalized in autumn 2017.
